Evommune (NYSE:EVMN) Insider Sells 1,488 Shares

Evommune, Inc. (NYSE:EVMN) insider Jeegar Pravinkumar Patel sold 1,488 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $22.50, for a total value of $33,480.00. Following the completion of the sale, the insider owned 46,403 shares in the company, valued at $1,044,067.50. This represents a 3.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Jeegar Pravinkumar Patel also recently made the following trade(s):

• On Monday, June 1st, Jeegar Pravinkumar Patel sold 16,687 shares of Evommune stock. The shares were sold at an average price of $22.74, for a total value of $379,462.38.

Evommune Stock Down 3.0%

NYSE EVMN traded down $0.72 during trading on Wednesday, hitting $23.53. The stock had a trading volume of 1,043,288 shares, compared to its average volume of 453,427. The company has a market capitalization of $847.59 million and a PE ratio of -2.48. The firm has a 50 day moving average price of $23.14 and a 200 day moving average price of $22.27. Evommune, Inc. has a twelve month low of $13.89 and a twelve month high of $33.20.

Evommune (NYSE:EVMN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.83) by $0.19. On average, sell-side analysts anticipate that Evommune, Inc. will post -2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Oppenheimer began coverage on Evommune in a report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price target on the stock. Royal Bank Of Canada reissued an “outperform” rating and set a $48.00 price objective on shares of Evommune in a research report on Friday, April 10th. Stifel Nicolaus initiated coverage on shares of Evommune in a research note on Friday, May 1st. They set a “buy” rating and a $54.00 target price on the stock. Morgan Stanley raised their target price on shares of Evommune from $54.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, May 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Evommune in a research note on Tuesday, May 26th. Three research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $49.25.

Hedge Funds Weigh In On Evommune

Several large investors have recently bought and sold shares of EVMN. Capricorn Fund Managers Ltd acquired a new stake in Evommune in the fourth quarter valued at $1,027,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Evommune during the 4th quarter worth about $34,000. Sectoral Asset Management Inc. purchased a new position in shares of Evommune in the 4th quarter valued at about $10,084,000. Geode Capital Management LLC purchased a new position in shares of Evommune in the 4th quarter valued at about $1,881,000. Finally, Seven Grand Managers LLC acquired a new stake in shares of Evommune during the 4th quarter worth about $1,284,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.